"Our third quarter results reflect our determination to pursue Atrium's business plan, which is focused on maintaining strong organic growth, facilitating the smooth and rapid integration of acquired companies and pursuing our proactive prospecting aimed at identifying new targets for acquisition that are both financially and commercially promising. These ingredients, which have ensured our success to date and represent Atrium's key principles, will continue to guide us in our present and future development plans", added Dr. Serge Yelle, Executive Vice-President, Health & Nutrition Division.
Active Ingredients & Specialty Chemicals Division
Revenues from the Active Ingredients & Specialty Chemicals Division were US$50.0 million for the third quarter ended September 30, 2007, representing an increase of 11.1% over revenues of US$45.0 million for the same period in 2006. EBITDA was US$4.0 million for the third quarter of 2007, representing an increase of 6.7% over 2006 EBITDA of US$3.7 million. This increase is attributable to organic growth and to the development of new markets.
"Our growth performance for the last quarter is very satisfactory. Our growth rate in 2007, which is superior to that of our main competitors, allows us to pursue our initiatives in order to follow through with our strategy to offer our targeted customers a global solution in all our markets", said Charles Boulanger, President of the Active Ingredients & Specialty Chemicals Division.
Atrium Innovations Inc. is a recognized leading developer, manufacturer
and marketer of science-based products for the cosmetics, pharmaceutical,
chemical and nutrition industries. The Company focuses primarily on growing
|SOURCE Atrium Innovations Inc.|
Copyright©2007 PR Newswire.
All rights reserved